# INTELLIGENT BIO SOLUTIONS INC. (INBS) — capital_raise/private_placement [announced]
Source: sec.gov · situation sit_dc679b997a11601283b5 · public 3608196177816851736 · retrieved 2026-09-03T11:46:48.556Z

## Overview
Intelligent Bio Solutions Inc. develops the Intelligent Fingerprinting Drug Screening System for commercial marketing and sale.

On August 31, 2026, Intelligent Bio Solutions Inc. entered into a Securities Purchase Agreement with a single institutional investor for a private placement offering that closed on September 2, 2026. The Company sold 2,036,659 shares of common stock (or Series M Pre-Funded Warrants in lieu thereof), Series N-1 warrants to purchase 2,036,659 shares, and Series N-2 warrants to purchase 2,036,659 shares. The combined purchase price was $2.455 per unit. The gross proceeds were approximately $5.0 million, before deducting placement agent fees and offering expenses. The Pre-Funded Warrants are exercisable at $0.01 per share, while the Series N-1 and Series N-2 Warrants are exercisable at $2.33 per share. The Series N-1 Warrants are callable following FDA 510(k) clearance for the Company's Intelligent Fingerprinting Drug Screening System, and the Series N-2 Warrants are exercisable upon shareholder approval.

## Terms
- Counterparty: Single institutional investor · Deal value: $5.0M · Consideration: mixed · Price/share: $2.455

## Key dates
- Announced 2026-09-02

## Timeline
- 2026-09-02 · 8-K (0001493152-26-041253): 8-K - INTELLIGENT BIO SOLUTIONS INC. — *Intelligent Bio Solutions Inc. develops the Intelligent Fingerprinting Drug Screening System for commercial marketing and sale.* On August 31, 2026, Intelligent Bio Solutions Inc. entered into a Securities Purchase Agreement with a single institutional investor for a private placement offering that closed on September 2, 2026. The Company sold 2,036,659 shares of common stock (or Series M Pre-Funded Warrants in lieu thereof), Series N-1 warrants to purchase 2,036,659 shares, and Series N-2 warrants to purchase 2,036,659 shares. The combined purchase price was $2.455 per unit. The gross proceeds were approximately $5.0 million, before deducting placement agent fees and offering expenses. The Pre-Funded Warrants are exercisable at $0.01 per share, while the Series N-1 and Series N-2 Warrants are exercisable at $2.33 per share. The Series N-1 Warrants are callable following FDA 510(k) clearance for the Company's Intelligent Fingerprinting Drug Screening System, and the Series N-2 Warrants are exercisable upon shareholder approval.
  https://www.sec.gov/Archives/edgar/data/1725430/0001493152-26-041253.txt

## Citations
- 0001493152-26-041253 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000149315226041253